Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.

IF 1.5 4区医学 Q3 HEMATOLOGY

Therapeutic Apheresis and Dialysis Pub Date : 2023-12-01 Epub Date: 2023-07-03 DOI:10.1111/1744-9987.14033

Kan Kikuchi, Masaomi Nangaku, Munekazu Ryuzaki, Tomoyuki Yamakawa, Yoshihiro Ota, Norio Hanafusa, Ken Sakai, Yoshihiko Kanno, Ryoichi Ando, Toshio Shinoda, Shu Wakino, Hidetomo Nakamoto, Yoshiaki Takemoto, Tadao Akizawa

{"title":"Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic.","authors":"Kan Kikuchi, Masaomi Nangaku, Munekazu Ryuzaki, Tomoyuki Yamakawa, Yoshihiro Ota, Norio Hanafusa, Ken Sakai, Yoshihiko Kanno, Ryoichi Ando, Toshio Shinoda, Shu Wakino, Hidetomo Nakamoto, Yoshiaki Takemoto, Tadao Akizawa","doi":"10.1111/1744-9987.14033","DOIUrl":null,"url":null,"abstract":"Introduction: In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID-19 was investigated using a registry of COVID-19 in Japanese dialysis patients.Methods: Dialysis patients with confirmed SARS-CoV-2 during the COVID-19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared.Results: A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group (p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID-19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively).Conclusion: Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":" ","pages":"1064-1069"},"PeriodicalIF":1.5000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Apheresis and Dialysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1744-9987.14033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID-19 was investigated using a registry of COVID-19 in Japanese dialysis patients.

Methods: Dialysis patients with confirmed SARS-CoV-2 during the COVID-19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared.

Results: A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group (p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID-19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively).

Conclusion: Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.

查看原文本刊更多论文

在奥密克戎（BA.1和BA.2）大流行期间，莫努匹拉韦和索特罗维单抗在日本新冠肺炎透析患者临床实践中的疗效。

简介：在本研究中，使用日本透析患者的新冠肺炎登记表，研究了sotrovimab和molnupiravir对新冠肺炎透析患者的疗效。方法：对新冠肺炎（奥密克戎BA.1和BA.2）大流行期间确诊的SARS-CoV-2透析患者进行分析。患者被分为四个治疗组：莫努匹拉韦单药治疗组（莫努匹拉韦组）、索特罗维单抗单药治疗（索特罗维单抗组）、莫努匹拉维和索特罗韦单抗联合治疗组（联合组）和无抗病毒治疗组（对照组）。比较了四组患者的死亡率。结果：共纳入1480例患者。molnupiravir、sotrovimab和联合用药组的死亡率与对照组相比有显著改善（p 结论：Sotrovimab对奥密克戎BA.1有疗效，但对BA.2有减弱作用。莫努匹拉韦在BA.2中也显示出疗效，这表明给予莫努匹拉韦是很重要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Apheresis and Dialysis 医学-泌尿学与肾脏学

CiteScore

3.00

自引率

10.50%

发文量

166

审稿时长

6-12 weeks

期刊介绍： Therapeutic Apheresis and Dialysis is the official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis and the Japanese Society for Dialysis Therapy. The Journal publishes original articles, editorial comments, review articles, case reports, meeting abstracts and Communications information on apheresis and dialysis technologies and treatments.